Summary
Amgen Inc. (AMGN) filed an 8-K on July 30, 2015, primarily to report its financial results for the second quarter and first half of 2015, as detailed in a press release issued on July 30, 2015. The filing includes a discussion of both U.S. GAAP and certain non-GAAP financial measures, such as adjusted earnings per share and free cash flow, with reconciliations provided to facilitate investor understanding. Additionally, the report announces a significant board appointment: Fred Hassan was elected as a director, effective immediately. Mr. Hassan brings extensive experience in the pharmaceutical and private equity sectors, having previously held CEO and Chairman roles at major companies like Schering-Plough and Pharmacia. He will serve on the Audit Committee and the Compensation and Management Development Committee, and his compensation arrangements, including a retainer and equity grant, are outlined. This appointment could signal a focus on strategic guidance and financial oversight.
Key Highlights
- 1Amgen reported its unaudited financial results for the three and six months ended June 30, 2015.
- 2The company utilized and explained certain non-U.S. GAAP financial measures, including adjusted EPS and free cash flow, in its earnings release.
- 3Fred Hassan was appointed to Amgen's Board of Directors, effective immediately on July 28, 2015.
- 4Mr. Hassan has a strong background in the pharmaceutical industry, previously serving as CEO of Schering-Plough and Pharmacia.
- 5He also possesses experience in private equity as a Partner and Managing Director at Warburg Pincus.
- 6Mr. Hassan will serve on the Audit Committee and the Compensation and Management Development Committee.
- 7His compensation includes a pro-rated annual retainer, committee meeting fees, expense reimbursement, and a pro-rated restricted stock unit grant.